Please note: AABB reserves the right to make updates to this program.
Wednesday, May 13, 2020
2:00 – 3:00 PM (ET) 7:00 – 8:00 PM (GMT)
Master Program Number: 20EL-531 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Transfusion Medicine
Intended Audience: Hospitals, Hospital Blood Banks, Immunohematology Reference Labs (IRL’s), Laboratory Staff, Managers/Supervisors, Nurses, Physicians, Residents/Fellows, Scientists, Students (MD, MT, SBB), Technologists, Transfusion Safety Officers
Teaching Level: Basic to Advanced
Director/Moderator: Thandar Aye, MLS(ASCP)SBB, Senior Reference Laboratory Technologist, BloodworksNW, Seattle, WA
Speaker: Moritz Stolla, MD, PhD, Director, Platelet Transfusion Research, BloodworksNW, Associate Medical Director, Swedish Medical Center Transfusion Service, Assistant Professor of Medicine, Division of Hematology, University of Washington School of Medicine, Seattle, WA
After participating in this educational activity, participants should be able to:
- Discuss the history of cold-stored platelets.
- Identify the advantages and disadvantages of platelet “cold-lesion”.
- Describe technical details such as platelet collection methods, storage conditions and evaluation of platelet function.
- Discuss which patient population is likely to profit from most from cold-stored platelet transfusions.
- Describe specific conditions and regulations related to platelet additive solutions and cold stored platelets.
Platelet additive solution (PAS) underwent many modifications since developed in 1980s. In this program, the speaker will discuss the latest developments in platelet storage as well as clinical implications in transfusion of PAS-platelets. Cold platelets were first introduced and routinely used in the 1960-70s. They were discontinued when it was found that the circulation time after transfusion is severely shortened. Cold-stored platelets recently gained attention as specific hemostatic product for actively bleeding patients. The speaker will outline the history, biological changes and technical details of cold-stored platelets and give a future outlook on applications. At the end of this program, participants should be able to answer the following questions:
- History: When were cold-stored platelets first introduced? Why were cold platelets discontinued? Why were cold-platelets being re-considered at this point in time?
- Platelet transfusion biology: What happens when we expose platelets to cold temperature? What are the downsides of the platelet “cold-lesion”, are there advantages?
- Technical details: Storage time, collection methods, PAS versus plasma, storage temperature, how to test for platelet function?
- Patient populations: Which patient population is likely to profit most from cold-stored platelet transfusions: Thrombocytopenic patients versus trauma patients versus surgery patients?
- Specific conditions/questions: TRALI, pathogen reduction, volume reduction, FDA approval of cold-stored platelets and PAS / variance discussion.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||
Continuing Education Credit
AABB estimates both the live and on-demand version of this eCast each to be eligible for 1 continuing education credits/contact hours for Physicians, California Nurse, California Lab Personnel, Florida Lab Personnel and General Participation credit. The final number of credit(s) and credit types awarded for this program (live or on-demand) will be determined by the program duration. For more information on each credit type please visit our
Continuing Education Credits webpage.
Disclosures for the planners of this event can be found here. Disclosures for the program faculty are provided at the beginning of the program.
Dr. Moritz Stolla is a physician scientist with a clinical background in internal medicine and clinical pathology. His research background is in platelet transfusion, vascular biology, and thrombosis/hemostasis. A major focus of Dr. Stolla’s research is to improve platelet transfusions and to evaluate alternative platelet products.